The first 60 days: Extensive-stage small-cell lung cancer

Below, week by week, is what OnCo's record of Extensive-stage small-cell lung cancer says about the first two months: the order is typical, the timing is yours to ask about. Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse. Sections appear only where the record has something to say. Orientation, not medical advice.

Weeks 1 to 2

What happens now

Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.

Biomarkers your report may list

Stage by PET-CT and brain MRI Platinum-free interval at relapse (sensitive versus resistant)DLL3 expression (nearly universal; not required for tarlatamab)B7-H3 (ifinatamab deruxtecan trials)Transcription factor subtype and SLFN11 (research)PD-L1 and tumour mutational burden (not predictive in small-cell disease)

Ask which of these were tested and what the results were; see the report reader for what each value means.

Tests and imaging linked to this cancer

MRI PET/CT MRD / molecular residual disease testing

Weeks 1 to 3

Who is on your team

These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.

A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.

Weeks 2 to 6

Decisions coming up

Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.

1.First line NCCN Guidelines: Small Cell Lung Cancer
Four cycles of carboplatin or cisplatin plus etoposide with atezolizumab (IMpower133) or durvalumab (CASPIAN), then maintenance immunotherapy until progression; lurbinectedin added to atezolizumab maintenance (IMforte); serplulimab, adebrelimab or benmelstobart in China.
Platinum + etoposide (EP / CE)Carboplatin Cisplatin Etoposide Atezolizumab IMpower133 Durvalumab CASPIAN Lurbinectedin IMforte Serplulimab ASTRUM-005 Adebrelimab Benmelstobart Maintenance therapy
2.Brain NCCN Guidelines: Small Cell Lung Cancer
MRI surveillance every three months or prophylactic cranial irradiation after response to first-line treatment; whole-brain or stereotactic radiotherapy for metastases.
Prophylactic cranial irradiation vs MRI surveillance Prophylactic cranial irradiation (PCI)EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer MRI Whole-brain radiotherapy (WBRT)Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)
3.Thoracic consolidation NCCN Guidelines: Small Cell Lung Cancer
Consolidative thoracic radiotherapy (30 Gy in 10 fractions) for patients with residual chest disease after chemotherapy.
IMRT / IGRT (modern external beam)Hypofractionated radiotherapy Consolidation therapy
4.Second line NCCN Guidelines: Small Cell Lung Cancer
Tarlatamab (DeLLphi-304) with inpatient monitoring for cytokine release syndrome during the first doses; lurbinectedin or topotecan as alternatives; platinum-etoposide rechallenge if relapse is more than six months after first line.
Tarlatamab DeLLphi-304 T-cell engagers (bispecific)Cytokine release syndrome (CRS)ICANS (neurotoxicity)Step-up dosing (T-cell engagers)Lurbinectedin Topotecan Platinum + etoposide (EP / CE)

Every visit

Questions to ask at each visit

Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.

Newly diagnosed

What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
Which biomarkers have been tested on my tumour (for example Stage by PET-CT and brain MRI, Platinum-free interval at relapse, DLL3 expression, B7-H3, Transcription factor subtype and SLFN11), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Extensive-stage small-cell lung cancer, first line, Extensive-stage small-cell disease with brain metastases at diagnosis, Relapsed small-cell lung cancer, platinum-sensitive.
Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.

First line

For my situation (first line), which of the standard options do you recommend and why?Guideline options include: Four cycles of carboplatin or cisplatin plus etoposide with atezolizumab (IMpower133) or durvalumab (CASPIAN), then maintenance immunotherapy until progression; lurbinectedin added to atezolizumab maintenance (IMforte); serplulimab, adebrelimab or benmelstobart in China.
Am I a candidate for Platinum + etoposide (EP / CE), Carboplatin, Cisplatin or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of IMpower133 and CASPIAN apply to someone like me?Trial populations differ from individual patients; ask how closely you match.

Second line

For my situation (second line), which of the standard options do you recommend and why?Guideline options include: Tarlatamab (DeLLphi-304) with inpatient monitoring for cytokine release syndrome during the first doses; lurbinectedin or topotecan as alternatives; platinum-etoposide rechallenge if relapse is more than six months after first line.
Am I a candidate for Tarlatamab, Lurbinectedin, Topotecan or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of DeLLphi-304 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.

Brain

For my situation (brain), which of the standard options do you recommend and why?Guideline options include: MRI surveillance every three months or prophylactic cranial irradiation after response to first-line treatment; whole-brain or stereotactic radiotherapy for metastases.
How do the results of EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer and Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer apply to someone like me?Trial populations differ from individual patients; ask how closely you match.

Thoracic consolidation

For my situation (thoracic consolidation), which of the standard options do you recommend and why?Guideline options include: Consolidative thoracic radiotherapy (30 Gy in 10 fractions) for patients with residual chest disease after chemotherapy.

Any stage

Are there clinical trials I could join, for example of Ifinatamab deruxtecan, IDeate-Lung02, DeLLphi-305, Actinium-225 DOTATATE?Trials are how the next standard of care is set; asking early keeps options open.
Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
I read that “No biomarker identifies the minority who gain long-term benefit from immunotherapy; PD-L1 and mutational burden do not work in small-cell disease”. How does that affect my plan?Open problems are where trials and second opinions matter most.
I read that “Tarlatamab needs inpatient monitoring for cytokine release syndrome, which limits access outside specialist centres”. How does that affect my plan?Open problems are where trials and second opinions matter most.

Weeks 3 to 8

Trials to ask about

Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.

From day one

Help that costs nothing

Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.

Any time

What to read next

Words this page and the cancer page use

Step-up dosing (T-cell engagers): Starting a bispecific T-cell engager (teclistamab, glofitamab, epcoritamab, tarlatamab) at a tiny dose and increasing it over the first week, so T cells are switched on gradually and the fever-and-low-blood-pressure reaction (cytokine release syndrome) stays mild.
Limited-stage vs extensive-stage (small-cell lung cancer): Small-cell lung cancer uses a two-way split instead of the usual four stages: limited (confined to one side of the chest and treatable within one radiation field, about a third of patients) or extensive (everything else).
Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11: Small-cell lung cancer has looked like one disease for fifty years; RNA profiling now splits it by the master transcription factor in charge (ASCL1, NEUROD1, POU2F3, or none with an inflamed signature), and these groups, plus the DNA-damage protein SLFN11, are the first leads for matching drugs to a cancer that has had almost no biomarkers.
Whole-brain radiotherapy (WBRT): Irradiating the entire brain, typically 30 Gy in 10 sessions, when metastases are too numerous or too widespread (leptomeningeal) for focused radiosurgery.
Prophylactic cranial irradiation (PCI): Giving the brain a preventive dose of radiation (25 Gy in 10 sessions) before any metastasis can be seen, mainly in small-cell lung cancer, which spreads to the brain in over half of patients.
Platinum-sensitive / platinum-resistant: Whether a cancer that responded to platinum chemotherapy came back more than six months later (sensitive, so platinum can be used again) or sooner (resistant, so something else is needed).
Consolidation therapy: Treatment given after a good response to kill the cancer cells that are presumably left but cannot be seen, to make the remission last.
ICANS (neurotoxicity): ICANS is confusion, speech difficulty, and rarely seizures after CAR-T or bispecific therapy.
Maintenance therapy: Ongoing, gentler treatment given after the main course has shrunk the cancer, to hold it in check for as long as possible rather than to shrink it further.
Cytokine release syndrome (CRS): A flood of inflammatory signals when immune cells are activated en masse, causing fever, low blood pressure, and sometimes organ failure.

Every term links to the glossary.